Substrate
financeSourced

Cornerstone Building Brands CFO John P. Roche Departs Effective June 2

Cornerstone Building Brands Inc. disclosed the departure of Chief Financial Officer John P. Roche in an 8-K filed with the SEC. The change triggers standard executive-transition disclosures and requires the company to identify a permanent or interim replacement in subsequent filings.

SEC EDGAR — Cornerstone Building Brands, Inc.
1 source·Jun 1, 8:00 PM·1m read
Cornerstone Building Brands CFO John P. Roche Departs Effective June 2realclearworld.com
Audio version
Tap play to generate a narrated version.

Cornerstone Building Brands Inc. reported that Chief Financial Officer John P. Roche left the company effective June 2, 2026.

The departure, disclosed in an 8-K filed with the SEC on the same date, falls under Item 5.02 — Departure of Directors or Certain Officers. The filing does not specify a successor or whether an interim CFO has been named. It also reports results under Item 5.07 for matters submitted to a vote of security holders at the company's most recent annual meeting, though specific vote tallies are not detailed in the summary record.

Prior to June 2, Roche served as the principal financial officer of the building-products manufacturer. The new state leaves the CFO position vacant until the board elects a replacement. Public companies must typically notify the SEC within four business days of a principal officer's departure and later disclose the appointment of any successor on Form 8-K.

The transition requires Cornerstone Building Brands to update its internal control certifications, Sarbanes-Oxley attestations and any debt-covenant or credit-agreement notices that reference the identity of the chief financial officer. Investors and counterparties will await a follow-on filing naming the new CFO or naming an interim officer, which in turn resets the timeline for the company's next quarterly certification of financial statements.

Failure to maintain a permanent or acting principal financial officer beyond standard grace periods can also affect the company's ability to file timely 10-Q and 10-K reports.

This marks the latest executive change at the CIK 0000883902 entity, which last appeared in SEC records for routine officer and shareholder-meeting disclosures. The company is required to file any material definitive agreements or press releases concerning the succession as separate exhibits or Form 8-K items in the coming weeks.

Coverage spread

Substrate’s article above is written from the primary record. Below: how mainstream outlets reported the same event.

No mainstream coverage of this story has surfaced yet.

Transparency

Confidence90%

Reported by a single outlet. This score reflects source tier and factual specificity — corroboration is limited with one source.

Related Stories

U.S. Strikes Botswana-Flagged Tanker in International Waters; Iran Blockade in Effectthehindu.com
finance42 min ago

U.S. Strikes Botswana-Flagged Tanker in International Waters; Iran Blockade in Effect

A U.S. aircraft fired an AGM-114 Hellfire missile into the engine room of the M/T Lexie on Tuesday, disabling the unladen vessel as it headed toward Kharg Island. The strike followed repeated ignored warnings over 24 hours.

FI
FI
OS
BBC News
4 sources
Fed Chairman Names Two Outside Advisers During Transitionprnewswire.com
finance42 min ago

Fed Chairman Names Two Outside Advisers During Transition

Federal Reserve Chairman Kevin Warsh appointed two interim advisers shortly after taking the post. One previously contributed to a conservative plan calling for major changes at the central bank.

FI
Wall Street Journal
2 sources
Forte Biosciences Accepts Resignation of Director David Veitchinsidermonkey.com
finance2 hrs agoSourced

Forte Biosciences Accepts Resignation of Director David Veitch

Forte Biosciences disclosed the resignation of independent director David Veitch from its board effective June 1 2026. The departure reduces the company's board size and triggers standard SEC and Nasdaq disclosure obligations for director changes at the clinical-stage biopharmace…

SEC EDGAR — Forte Biosciences, Inc. (FBRX)
1 source